BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 22714897)

  • 1. β-LGND2, an ERβ selective agonist, inhibits pathologic retinal neovascularization.
    Giddabasappa A; Eswaraka JR; Barrett CM; Bauler MN; Wu Z; Yepuru M; Miller DD; Dalton JT
    Invest Ophthalmol Vis Sci; 2012 Jul; 53(8):5066-75. PubMed ID: 22714897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ruboxistaurin, a PKCbeta inhibitor, inhibits retinal neovascularization via suppression of phosphorylation of ERK1/2 and Akt.
    Nakamura S; Chikaraishi Y; Tsuruma K; Shimazawa M; Hara H
    Exp Eye Res; 2010 Jan; 90(1):137-45. PubMed ID: 19825373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of ocular neovascularization by a novel peptide derived from human placenta growth factor-1.
    Zheng Y; Gu Q; Xu X
    Acta Ophthalmol; 2012 Nov; 90(7):e512-23. PubMed ID: 22994140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade.
    Ristori C; Filippi L; Dal Monte M; Martini D; Cammalleri M; Fortunato P; la Marca G; Fiorini P; Bagnoli P
    Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):155-70. PubMed ID: 20739470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic effect of betaine on pathologic retinal neovascularization via suppression of reactive oxygen species mediated vascular endothelial growth factor signaling.
    Park SW; Jun HO; Kwon E; Yun JW; Kim JH; Park YJ; Kang BC; Kim JH
    Vascul Pharmacol; 2017 Mar; 90():19-26. PubMed ID: 27473515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acetyl-11-keto-β-boswellic acid reduces retinal angiogenesis in a mouse model of oxygen-induced retinopathy.
    Lulli M; Cammalleri M; Fornaciari I; Casini G; Dal Monte M
    Exp Eye Res; 2015 Jun; 135():67-80. PubMed ID: 25913458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulating the hypoxia-inducible factor signaling pathway as a therapeutic modality to regulate retinal angiogenesis.
    DeNiro M; Alsmadi O; Al-Mohanna F
    Exp Eye Res; 2009 Nov; 89(5):700-17. PubMed ID: 19580810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy of a novel non-peptide αvβ3 integrin antagonist for pathological retinal angiogenesis in mice.
    Li YJ; Li XH; Wang LF; Kuang X; Hang ZX; Deng Y; Du JR
    Exp Eye Res; 2014 Dec; 129():119-26. PubMed ID: 25446322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T2-TrpRS inhibits preretinal neovascularization and enhances physiological vascular regrowth in OIR as assessed by a new method of quantification.
    Banin E; Dorrell MI; Aguilar E; Ritter MR; Aderman CM; Smith AC; Friedlander J; Friedlander M
    Invest Ophthalmol Vis Sci; 2006 May; 47(5):2125-34. PubMed ID: 16639024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Candesartan, an angiotensin II type 1 receptor antagonist, inhibits pathological retinal neovascularization by downregulating VEGF receptor-2 expression.
    Nakamura S; Tsuruma K; Shimazawa M; Hara H
    Eur J Pharmacol; 2012 Jun; 685(1-3):8-14. PubMed ID: 22543084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dipeptide Arg-Gln inhibits retinal neovascularization in the mouse model of oxygen-induced retinopathy.
    Neu J; Afzal A; Pan H; Gallego E; Li N; Li Calzi S; Caballero S; Spoerri PE; Shaw LC; Grant MB
    Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):3151-5. PubMed ID: 16799062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apatinib, an Inhibitor of Vascular Endothelial Growth Factor Receptor 2, Suppresses Pathologic Ocular Neovascularization in Mice.
    Kim KL; Suh W
    Invest Ophthalmol Vis Sci; 2017 Jul; 58(9):3592-3599. PubMed ID: 28715845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-angiogenic effect of luteolin on retinal neovascularization via blockade of reactive oxygen species production.
    Park SW; Cho CS; Jun HO; Ryu NH; Kim JH; Yu YS; Kim JS; Kim JH
    Invest Ophthalmol Vis Sci; 2012 Nov; 53(12):7718-26. PubMed ID: 23099493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Herbimycin A inhibits angiogenic activity in endothelial cells and reduces neovascularization in a rat model of retinopathy of prematurity.
    McCollum GW; Rajaratnam VS; Bullard LE; Yang R; Penn JS
    Exp Eye Res; 2004 May; 78(5):987-95. PubMed ID: 15051479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-angiogenic effects of a mutant endostatin: a new prospect for treating retinal and choroidal neovascularization.
    Bai Y; Zhao M; Zhang C; Li S; Qi Y; Wang B; Huang L; Li X
    PLoS One; 2014; 9(11):e112448. PubMed ID: 25380141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcitriol is a potent inhibitor of retinal neovascularization.
    Albert DM; Scheef EA; Wang S; Mehraein F; Darjatmoko SR; Sorenson CM; Sheibani N
    Invest Ophthalmol Vis Sci; 2007 May; 48(5):2327-34. PubMed ID: 17460298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fractalkine, a CX3C chemokine, as a mediator of ocular angiogenesis.
    You JJ; Yang CH; Huang JS; Chen MS; Yang CM
    Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):5290-8. PubMed ID: 17962485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of pathologic retinal neovascularization by a small peptide derived from human apolipoprotein(a).
    Zhao H; Jin H; Li Q; Gu Q; Zheng Z; Wu H; Ye S; Sun X; Xu X; Ho PC
    Invest Ophthalmol Vis Sci; 2009 Nov; 50(11):5384-95. PubMed ID: 19515999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity.
    Wilkinson-Berka JL; Jones D; Taylor G; Jaworski K; Kelly DJ; Ludbrook SB; Willette RN; Kumar S; Gilbert RE
    Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1600-5. PubMed ID: 16565398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenesis effects of endostatin in retinal neovascularization.
    Bai YJ; Huang LZ; Zhou AY; Zhao M; Yu WZ; Li XX
    J Ocul Pharmacol Ther; 2013 Sep; 29(7):619-26. PubMed ID: 23545016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.